文献速递免疫规划

鸡蛋源与细胞源流感疫苗诱导的神经氨酸酶抑制抗体应答比较

Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.
PubMed 文献 · Vaccine · 2025-01-05

在2018-2019和2019-2020流感季的临床试验免疫原性子研究中,比较鸡蛋源灭活流感疫苗(eIIV)与细胞源灭活流感疫苗(cIIV)诱导的神经氨酸酶抑制(NAI)抗体应答。结果显示,两种疫苗对N1组分的应答不同,第1年eIIV接种者43.5%出现NAI滴度4倍升高而cIIV接种者无一人出现;对N2组分的应答率和抗体滴度相似。NAI应答与血凝素特异性中和抗体应答无相关性。

要点

  • 第1年eIIV接种者43.5%出现N1 NAI滴度4倍升高,cIIV接种者无一人出现。
  • 两种疫苗对N2组分的应答率和抗体滴度相似。
  • NAI应答与HA特异性中和抗体应答无相关性。

核心结论

  • 接种eIIV与cIIV后针对NA的抗体应答不相同;eIIV对N1和N2组分的应答相似,而cIIV对N1的应答者少于N2。
  • 作者认为需开展研究以确定NA免疫对流感疫苗效果的影响。

研究设计与样本

  • 在比较鸡蛋源、细胞源和重组血凝素源流感疫苗效果的临床试验中开展免疫原性子研究,覆盖2018-2019和2019-2020流感季。
  • 检测疫苗接种前和接种后血清中对疫苗A(H1N1)pdm09和A(H3N2)组分的NAI和中和抗体滴度。

主要发现

  • 第1年和第2年eIIV与cIIV对N1组分的应答均不同,而鸡蛋源与细胞源疫苗对N2组分的应答率和抗体滴度相似。
  • 第1年eIIV接种者43.5%出现NAI滴度4倍升高,cIIV接种者无一人出现。
  • 两种疫苗类型对N1和N2的应答之间均呈弱正相关,但NAI与HA特异性中和抗体应答之间无相关性。
  • 不含NA的重组HA疫苗作为特异性对照,接种者NAI抗体滴度未升高,仅2例推测为亚临床感染者例外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Neuraminidase (NA)-specific antibodies contribute to immunity against influenza. While studies have demonstrated increased NA inhibiting (NAI) antibody titers after vaccination with egg-derived inactivated influenza vaccines (eIIV), the response to cell culture-derived (c) IIV has not been reported. METHODS: An immunogenicity sub-study was performed within a clinical trial comparing the effectiveness of egg, cell, and recombinant hemagglutinin (HA)-derived influenza vaccines during the 2018-2019 and 2019-2020 influenza seasons. NAI and neutralizing antibody titers against the A(H1N1)pdm09 and A(H3N2) components of the vaccines were measured in pre- and post-vaccination sera. RESULTS: Responses to the N1 component of eIIV and cIIV were different in both study years 1 and 2 whereas response rate and antibody titers to the N2 component of egg and cell culture-derived vaccines were similar. For example, 43.5 % of eIIV and no cIIV recipients had four-fold NAI titer increases in year 1. There was a weak positive correlation between responses to N1 and N2 for both vaccine types but no correlation between NAI and HA-specific neutralizing antibody responses. Recombinant HA vaccine that does not contain NA served as a specificity control; NAI antibody titers did not increase in recipients except in two individuals presumed to have subclinical infection. CONCLUSION: Antibody responses to NA following vaccination with eIIV and cIIV were not the same; although the responses to the N1 and N2 components of eIIV were similar, there were fewer responders to N1 than N2 of cIIV. Studies to determine the impact of NA immunity on influenza vaccine effectiveness are warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Alvarado-Facundo E, Herrup R, Wang W, et al. Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines. Vaccine. 2025. PMID: 39754936. doi:10.1016/j.vaccine.2024.126669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。